Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Gerard Ferguson
Theratechnologies IncTH.TOTOP PICKJul 10, 2017
Gerard FergusonOwned
$8.24
Stock price when the opinion was issued
$4.47
As of Sep 26, 2025. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
PARTIAL BUY
Every biotech company always has some life-altering technology, and it's always way too positive. Small-mid caps like this can have big moves. Reversing a sideways trend, and breaking up to new levels, so that's positive. Maybe some movement up to $12. Take a small position, don't expose yourself too much. Support will be around $8.50, and if it breaks, start exiting.
biotechnologypharmaceutical
BUY
Canadian. Excellent phase 3 product results. A take over target, in a position of being sold right now. They have lots of cash. At this level it’s a dollar below financing. Good product. Would buy at this price.
Peter HodsonOwned
biotechnologypharmaceutical
BUY
Excellent phase 3 results. They are a takeover target, they have lots of cash. Annoyed at management because last month they had 61 million in cash, and decided to put the company up for sale, while at the same time decided to raise money. They can't have it both ways.
Nothing wrong with the product. Good one to hold and to buy. Should be stable.
Peter HodsonOwned
biotechnologypharmaceutical
BUY
Had 2 good phase 3 trials. 2nd trial is going on right now. Long-term data was very effective. FDA approval will probably happen in the next year. Probably the best takeout candidate in a biotechnology space.
Peter HodsonOwned
biotechnologypharmaceutical
STRONG BUY
Bought today. Have had great results on their phase 3. They've done their financing, they've got their cash. Go to market probably in 2010, 2011.
Likely will be acquired. Mixed view of what the drug could be worth.
Peter HodsonOwned
biotechnologypharmaceutical
They are taking the profits and cash flow from their drug to introduce a second drug, expected next year. (Analysts’ target: $9.50).